MedTrace Logo

Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer

NCT02079324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-08-22

No results posted yet for this study

Summary

The purpose of this research is to evaluate MTD, Safety and efficacy of GX-051 after intratumoral injection in head and neck cancer patience.

Conditions

Interventions

BIOLOGICAL

GX-051

intratumoral injection

Sponsors & Collaborators

  • Genexine, Inc.

    lead INDUSTRY

Principal Investigators

  • Minsik Kim, M.D. · Seoul St.Mary's Hospital of the Catholic University of Korea

  • Hyun-Tak Jin, ph.D. · Genexine, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02079324 on ClinicalTrials.gov